Is a Bone Marrow Biopsy Required to Diagnose MCAS?
At a Glance
A bone marrow biopsy is not typically required to diagnose Mast Cell Activation Syndrome (MCAS). Most cases are diagnosed using clinical symptoms, treatment response, and lab tests during flares. Biopsies are reserved for patients with red flags for a primary clonal mast cell disorder.
If you are being evaluated for suspected Mast Cell Activation Syndrome (MCAS), you do not typically need a bone marrow biopsy. A diagnosis of MCAS is primarily based on clinical symptoms, blood or urine tests showing elevated mast cell mediators during a flare, and whether your symptoms improve with mast cell-targeted treatments [1][2]. For the vast majority of patients with MCAS—specifically those with idiopathic or secondary MCAS—a bone marrow biopsy is unnecessary.
However, a bone marrow biopsy becomes an important diagnostic tool if your doctor suspects a different, rarer type of mast cell disorder caused by a genetic mutation, such as Systemic Mastocytosis (SM) or Monoclonal MCAS (MMAS) [3][4].
Why Are Bone Marrow Biopsies Discussed in MCAS?
Mast cell diseases are broadly divided into categories based on what is causing the mast cells to misbehave.
- Secondary MCAS: Mast cells are reacting to a clear trigger, such as a known allergy, infection, or other inflammatory condition [4].
- Idiopathic MCAS: Mast cells are overactive, but no specific external trigger or genetic mutation can be found [1].
- Primary (Clonal) Mast Cell Disorders: Mast cells have a genetic mutation that causes them to abnormally multiply or remain constantly active. This category includes Systemic Mastocytosis (SM) and Monoclonal MCAS (MMAS) [3].
A bone marrow biopsy is used specifically to look for the “clonality” (genetic mutations and abnormal clustering of mast cells in the bone marrow) seen in primary mast cell disorders [5][6]. If your doctor suspects your symptoms are driven by idiopathic or secondary MCAS, there is no need to look for these clusters in your bone marrow.
When Might a Bone Marrow Biopsy Be Recommended?
Your medical team will look for specific “red flags” in your bloodwork and physical exam to determine if a primary mast cell disorder is a possibility. A bone marrow biopsy may be recommended if you have:
- Persistently Elevated Baseline Tryptase: Tryptase is an enzyme released by mast cells. In MCAS, tryptase or other mast cell mediators may spike during a flare [7]. (Doctors often look for an increase of 20% plus 2 ng/mL above your baseline to confirm a flare [8]). However, if your baseline tryptase (measured when you are feeling well) is persistently elevated—particularly above 20 ng/mL—it is a strong indicator that a bone marrow biopsy might be needed [9][10].
- A Positive KIT D816V Blood Test: This is a specific genetic mutation found in the vast majority of people with systemic mastocytosis. Advanced blood tests (like ddPCR) can often detect this mutation using a standard blood draw from your arm (peripheral blood). If it is positive, a biopsy is usually required to confirm the diagnosis [11][12].
- Unexplained or Venom-Triggered Severe Anaphylaxis: Repeated, severe allergic reactions that cause drops in blood pressure (shock), especially if there is no identifiable trigger (like food), or if they are specifically triggered by insect stings (like bees or wasps), which is a known red flag for clonal mast cell disease [13].
- Physical or Hematological Signs: Findings such as an enlarged spleen or liver (which might feel like unexplained fullness or pain in your upper abdomen), unexplained low blood cell counts (evaluated via a standard CBC blood test), or specific skin rashes like urticaria pigmentosa (reddish-brown spots that hive when rubbed) [14][9].
A Note on Diagnostic Challenges
While looking for elevated mediators in blood or urine is the standard alternative to a biopsy, catching these mediators is notoriously difficult because they degrade rapidly, and 24-hour chilled urine tests can be hard to manage. It often requires repeated testing to successfully “catch” a flare [15][7].
Additionally, an elevated baseline tryptase does not automatically mean you need a bone marrow biopsy. A common genetic trait called Hereditary Alpha-Tryptasemia (HαT) causes naturally higher baseline tryptase levels without the presence of a primary mast cell disease [16]. Doctors often test for HαT with a simple cheek swab or blood test before deciding to proceed with an invasive procedure like a biopsy [17].
Summary
For most patients seeking an MCAS diagnosis, a thorough clinical history, careful tracking of symptoms, and standard blood and urine tests during symptom flares are the primary tools used. A bone marrow biopsy is an invasive test reserved for specific situations where bloodwork or clinical signs strongly point toward a primary clonal disorder like Systemic Mastocytosis [3][6].
Common questions in this guide
Do I need a bone marrow biopsy to be diagnosed with MCAS?
When would a doctor recommend a bone marrow biopsy for suspected MCAS?
What does a high baseline tryptase level mean?
Can a blood test replace a bone marrow biopsy for mast cell disease?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my baseline serum tryptase level, and how does it compare to my levels during a flare?
- 2.Based on my symptoms and lab work, do you suspect a primary clonal mast cell disorder, or idiopathic/secondary MCAS?
- 3.Can we test for Hereditary Alpha-Tryptasemia (HαT) or the KIT D816V mutation with a simple blood test before we discuss a biopsy?
- 4.What specific criteria are you using to determine if a bone marrow biopsy is necessary for my case?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (17)
- 1
Idiopathic mast cell activation syndrome is more often suspected than diagnosed-A prospective real-life study.
Buttgereit T, Gu S, Carneiro-Leão L, et al.
Allergy 2022; (77(9)):2794-2802 doi:10.1111/all.15304.
PMID: 35364617 - 2
Generalized pruritus relieved by NSAIDs in the setting of mast cell activation syndrome.
Kesterson K, Nahmias Z, Brestoff JR, et al.
The journal of allergy and clinical immunology. In practice 2018; (6(6)):2130-2131 doi:10.1016/j.jaip.2018.03.002.
PMID: 29577987 - 3
A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis.
Carter MC, Desai A, Komarow HD, et al.
The Journal of allergy and clinical immunology 2018; (141(1)):180-188.e3 doi:10.1016/j.jaci.2017.05.036.
PMID: 28629749 - 4
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome.
Valent P, Akin C, Bonadonna P, et al.
The journal of allergy and clinical immunology. In practice 2019; (7(4)):1125-1133.e1 doi:10.1016/j.jaip.2019.01.006.
PMID: 30737190 - 5
Mast Cell Activation Syndrome: Tools for Diagnosis and Differential Diagnosis.
Weiler CR
The journal of allergy and clinical immunology. In practice 2020; (8(2)):498-506 doi:10.1016/j.jaip.2019.08.022.
PMID: 31470118 - 6
Review and Updates on Systemic Mastocytosis and Related Entities.
Li JY, Ryder CB, Zhang H, et al.
Cancers 2023; (15(23)) doi:10.3390/cancers15235626.
PMID: 38067330 - 7
Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022.
Butterfield JH
The journal of allergy and clinical immunology. In practice 2022; (10(8)):1974-1984 doi:10.1016/j.jaip.2022.03.008.
PMID: 35346887 - 8
[Tryptase: A practical guide for the physician].
Lobbes H, Reynaud Q, Mainbourg S, et al.
La Revue de medecine interne 2020; (41(11)):748-755 doi:10.1016/j.revmed.2020.06.006.
PMID: 32712042 - 9
Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond.
Sprinzl B, Greiner G, Uyanik G, et al.
International journal of molecular sciences 2021; (22(5)) doi:10.3390/ijms22052458.
PMID: 33671092 - 10
Urticaria pigmentosa and systemic mastocytosis.
Keow J, Chin-Yee B, Hsia CC, Robertson K
Clinical case reports 2023; (11(12)):e8302 doi:10.1002/ccr3.8302.
PMID: 38111510 - 11
High-sensitivity KIT D816V variation analysis by droplet digital polymerase chain reaction: The reference laboratory perspective.
Shean RC, Hellwig S, Saadalla A, et al.
American journal of clinical pathology 2025; (164(2)):145-149 doi:10.1093/ajcp/aqaf008.
PMID: 40036308 - 12
Mast cell leukemia morphologic illustration of a rare entity.
Syposs CR, Evans AG, Bennett JM, et al.
EJHaem 2022; (3(4)):1422-1424 doi:10.1002/jha2.571.
PMID: 36467795 - 13
[Mast cell activation syndrome. About a clinical case].
Cardona R, Muñoz-Ávila MA, Gómez-Henao C, et al.
Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 2019; (66(4)):504-509 doi:10.29262/ram.v66i4.587.
PMID: 32105433 - 14
Solitary mastocytoma presenting in an adult: report and literature review of adult-onset solitary cutaneous mastocytoma with recommendations for evaluation and treatment.
Cohen PR
Dermatology practical & conceptual 2016; (6(3)):31-8 doi:10.5826/dpc.0603a07.
PMID: 27648381 - 15
Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome.
Butterfield JH
The journal of allergy and clinical immunology. In practice 2023; (11(8)):2542-2546 doi:10.1016/j.jaip.2023.02.017.
PMID: 36863614 - 16
From mechanism to management: CEREMAST perspectives on the intersection of HαT and clonal mast cell disorders.
Polivka L, Hermine O, Rossignol J
Frontiers in allergy 2025; (6()):1674609 doi:10.3389/falgy.2025.1674609.
PMID: 41306763 - 17
Hereditary alpha tryptasemia: elevated tryptase, female sex, thyroid disorders, and anaphylaxis.
Puxkandl V, Aigner S, Hoetzenecker W, Altrichter S
Frontiers in allergy 2024; (5()):1461359 doi:10.3389/falgy.2024.1461359.
PMID: 39600380
This page provides educational information about MCAS testing and bone marrow biopsies. Always consult your allergist or hematologist to determine the right diagnostic tests for your specific symptoms.
Get notified when new evidence is published on Mast Cell Activation Syndrome (MCAS).
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.